Morgan Stanley Aim Immuno Tech Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Morgan Stanley holds 85,320 shares of AIM stock, worth $32,421. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,320

Previous 77,318 10.35%

Holding current value

$32,421

Previous $34,000 17.65%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.33 - $0.48 $2,640 - $3,840	8,002 Added 10.35%	85,320 $40,000
Q4 2023 Feb 13, 2024	SELL	$0.4 - $0.56 $70,000 - $98,000	-175,000 Reduced 69.36%	77,318 $34,000
Q3 2023 Nov 15, 2023	SELL	$0.44 - $0.71 $80,625 - $130,100	-183,240 Reduced 42.07%	252,318 $116,000
Q2 2023 Aug 14, 2023	SELL	$0.4 - $0.67 $70,007 - $117,262	-175,019 Reduced 28.66%	435,558 $291,000
Q1 2023 May 15, 2023	SELL	$0.32 - $0.77 $97,943 - $235,675	-306,072 Reduced 33.39%	610,577 $262,000

Q4 2022 Feb 14, 2023	SELL	$0.31 - $0.6 $149,358 - $289,080	-481,800 Reduced 34.45%	916,649 $284,000
Q3 2022 Nov 14, 2022	SELL	$0.57 - $0.81 $114,487 - $162,692	-200,855 Reduced 12.56%	1,398,449 $814,000
Q2 2022 Oct 27, 2022	SELL	$0.78 - $1.27 $306,403 - $498,887	-392,825 Reduced 19.72%	1,599,304 $1.25 Million
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.27 $306,403 - $498,887	-392,825 Reduced 19.72%	1,599,304 $1.25 Million
Q1 2022 Oct 27, 2022	BUY	$0.67 - $1.18 $263,192 - $463,533	392,825 Added 24.56%	1,992,129 $2.11 Million
Q1 2022 May 13, 2022	SELL	$0.67 - $1.18 $32,999 - $58,118	-49,253 Reduced 2.41%	1,992,129 $2.11 Million
Q4 2021 Feb 14, 2022	SELL	$0.92 - $1.96 $315,557 - $672,274	-342,997 Reduced 14.39%	2,041,382 $1.88 Million
Q3 2021 Nov 15, 2021	BUY	$1.91 - $2.17 $4.55 Million - $5.17 Million	2,384,379 New	2,384,379 $4.82 Million

Others Institutions Holding AIM

# of Institutions

Shares Held

4.09M

Call Options Held

Put Options Held

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $18.3M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account